Immunic to Attend Key Conferences in June

Immunic, Inc., a biotechnology firm, announced its participation in several key investor, scientific, and industry conferences throughout June 2025. The company, known for its oral therapies targeting chronic inflammatory and autoimmune diseases, will engage at these events to showcase its ongoing research and foster strategic partnerships.

From June 3-5, CEO Daniel Vitt will present at the Jefferies Healthcare Conference in New York. Concurrently, team members will meet with investors. On June 10-13, Christian Gege, Head of Intellectual Property, will present preclinical data at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium in Denmark.

Additionally, the UBS Life Sciences Conference in London, and the BIO International Convention in Boston will see active participation from Immunic's leadership, aiming to enhance collaboration opportunities. The month concludes with participation at the European Academy of Neurology Congress in Helsinki, spotlighting vidofludimus calcium's potential in neuroprotection.